Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
Interventionsstudie
Phase 2
Fudan university shanghai cancer center, Deparment of gynecologic oncology
Sponsor: Fudan University
Zuletzt aktualisiert: 14. August 2024 Hinweis - Die Informationen stammen aus öffentlichen Registern und spiegeln möglicherweise nicht die Echtzeitänderungen am lokalen Studienzentrum wider.
This study aims to investigate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospective, single-arm, phase II clinical trial, to improve the overall treatment level and prognosis of platinum-resistant ovarian cancer.